Skip to main content
. 2016 Mar 2;7(15):19813–19823. doi: 10.18632/oncotarget.7852

Figure 4. RASSF6 inhibits the migration and invasion ability of colorectal cancer cells.

Figure 4

(A) Wound scratch assays were performed in LoVo cells with transfection of empty vector as control or RASSF6 (Left, A), and HT-29 cells with transfection of scrambled control siRNA or RASSF6 siRNA respectively. Images were visualized at 0 h, 24 h, and 48 h at a magnification of 100 ×. RASSF6 highly-expressed cells showed lower migration ability than RASSF6-low cells. (B) The migration ability was also assessed using Transwell chamber without Matrigel (18 h for LoVo and 48 h for HT-29 cells). (C) The effects of RASSF6 on the invasion ability of cancer cells were assessed by Matrigel-invasion assay (24 h for LoVo and 48 h for HT-29 cells). Representative images were visualized at a magnification of 100 ×. All data are showed as mean ± SE of three independent experiments, and for every single experiment, the data are mean of at least three fields, *P < 0.05.